Open AccessApplication of lercanidipine in the treatment of hypertension
Author(s) -
G. G Shehyan,
Шехян Грант Георгиевич,
A. A Yalymov,
Ялымов Анатолий Александрович,
В. С. Задионченко,
Задионченко Владимир Семенович,
С. И. Варенцов,
Варенцов Сергей Игоревич
Publication year - 2014
Publication title -
cardiosomatika
Language(s) - English
Resource type - Journals
eISSN - 2658-5707
pISSN - 2221-7185
DOI - 10.26442/cs45099
Subject(s) - lercanidipine , tolerability , medicine , blood pressure , essential hypertension , heart rate , drug , antagonist , cardiology , adverse effect , pharmacology , receptor
The article presents data from clinical trials that have examined the efficacy and safety of modern calcium antagonist (CA) III generation of lercanidipine. The results of studies show that treatment with lercanidipine leads to a marked reduction in systolic and diastolic blood pressure without significant effect on heart rate. Unique pharmacokinetic characteristics of the drug provide its excellent efficacy and safety, good tolerability, convenience, acceptance and high adherence CA data in patients with hypertension. Additional properties of lercanidipine allow us to recommend the use of the CA in comorbidity.